|
- Science | AAAS
The strength of Science and its online journal sites rests with the strengths of its community of authors, who provide cutting-edge research, incisive scientific commentary, and insights on what’s important to the scientific world
- Science Journal - AAAS
Science is a leading outlet for scientific news, commentary, and cutting-edge research Through its print and online incarnations, Science reaches an estimated worldwide readership of more than one million
- Science Family of Journals | AAAS
The Open Access journal Research, published in association with CAST, publishes innovative, wide-ranging research in life sciences, physical sciences, engineering and applied science
- Science Advances - AAAS
Science Advances is the American Association for the Advancement of Science’s (AAAS) open access multidisciplinary journal, publishing impactful research papers and reviews in any area of science, in both disciplinary-specific and broad, interdisciplinary areas
- The proteome of the late Middle Pleistocene Harbin individual - Science
Home Science Vol 389, No 6761 The proteome of the late Middle Pleistocene Harbin individual
- An orthogonal T7 replisome for continuous hypermutation and . . . - Science
Science 7 Aug 2025 Vol 389, Issue 6760 pp 618 - 622 DOI: 10 1126 science adp9583 Editor’s summary Abstract Establishing an orthogonal replication system based on the bacteriophage T7 replisome Engineering T7 DNA polymerase mutants with increased mutation rate Continuous evolution of TEM-1 β-lactamase Discussion Acknowledgments Supplementary
- Epigenetics and the evolution of instincts | Science
Epigenetics and the evolution of instincts Instincts may evolve from learning and share the same cellular and molecular mechanisms Gene E Robinson and Andrew B Barron Authors Info Affiliations Science 7 Apr 2017 Vol 356, Issue 6333 pp 26 - 27
- Sleep apnea pill shows striking success in large clinical . . . - Science
This medication is a big step in that direction ” Apnimed plans to present the full results of the trial at a conference this fall A second large, 12-month trial of the pill is expected to be complete this summer The company aims to apply for FDA approval by early 2026 doi: 10 1126 science zg1hhn8
|
|
|